molidustat drug acts hif prolylhydroxylase inhibitor thereby increases endogenous production erythropoietin stimulates production hemoglobin red blood cells phase iii clinical trials treatment anemia caused chronic kidney due potential applications athletic doping also incorporated screens performanceenhancing molidustat indicated control nonregenerative anemia associated chronic kidney disease us food drug administration fda conditionally approved may reasonable expectation effectiveness molidustat evaluated study conducted two first phase involved multicenter doublemasked randomized placebocontrolled field effectiveness safety second phase unmasked optional continuation field study enrolled cats years age various breeds breed mixes diagnosed nonregenerative anemia associated fda granted conditional approval elanco us drug article relating blood blood forming organs stub help wikipedia expanding httpsenwikipediaorgwikimolidustat